The Clinical Pharmacokinetics of Escitalopram
Author:
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 46 (4) , 281-290
Abstract
Escitalopram is the ( S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in...Keywords
This publication has 54 references indexed in Scilit:
- The pharmacokinetics of escitalopram in patients with hepatic impairmentThe AAPS Journal, 2006
- Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose studyDepression and Anxiety, 2004
- In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparationsMolecular Psychiatry, 2002
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Lack of Effect of Citalopram on the Steady-State Pharmacokinetics of Carbamazepine in Healthy Male SubjectsJournal of Clinical Psychopharmacology, 2001
- Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequencesInternational Journal of Neuropsychopharmacology, 2000
- Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarinBritish Journal of Clinical Pharmacology, 1997
- Cytochrome P450 EnzymesJournal of Clinical Psychopharmacology, 1996
- CitalopramTherapeutic Drug Monitoring, 1993
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992